Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Genitourinary 1

Conditions

Neoplasms 4Carcinoma, Transitional Cell 3Urinary Bladder Neoplasms 2Neoplasm Metastasis 2Head and Neck Neoplasms 2Small Cell Lung Carcinoma 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Adenocarcinoma of Lung 1Acrocephalosyndactylia 1

Interventions

pembrolizumab 8Pemetrexed 8capmatinib 7Carboplatin 7ceritinib 5Cisplatin 5Bevacizumab 4Docetaxel 3trametinib 2motexafin gadolinium 2aldesleukin 2Vinorelbine 2Paclitaxel 2Interleukin-2 2Gefitinib 2BID protein, human 2technetium 99m etarfolatide 1spartalizumab 1sintilimab 1satraplatin 1ribociclib 1picropodophyllin 1nazartinib 1naporafenib 1milademetan 1lazertinib 1fludarabine phosphate 1fludarabine 1farletuzumab 1enzalutamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Adenocarcinoma of Lung × Rogaratinib × Clear all
NCT01976741 2021-05-06

Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor (Rogaratinib)

Bayer

Phase 1 Completed
168 enrolled 59 charts
GenitourinaryHead & NeckThoracic

Adenocarcinoma of Lung, Urinary Bladder Neoplasms, Head and Neck Neoplasms, Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡